Literature DB >> 24516896

Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation.

Jaime Sanz, Francisco J Jaramillo, Dolores Planelles, Pau Montesinos, Ignacio Lorenzo, Federico Moscardó, Guillermo Martin, Francisca López, Jesús Martínez, Isidro Jarque, Javier de la Rubia, Luis Larrea, Miguel A Sanz, Guillermo F Sanz.   

Abstract

This retrospective study analyzed the impact of directional donor-recipient human leukocyte antigen (HLA) disparity using allele-level typing at HLA-A, -B, -C, and -DRB1 in 79 adults with acute myeloid leukemia (AML) who received single-unit umbilical cord blood (UCB) transplant at a single institution. With extended high-resolution HLA typing, the donor-recipient compatibility ranged from 2/8 to 8/8. HLA disparity showed no negative impact on nonrelapse mortality (NRM), graft-versus-host (GVH) disease or engraftment. Considering disparities in the GVH direction, the 5-year cumulative incidence of relapse was 44% and 22% for patients receiving an UCB unit matched ≥ 6/8 and < 6/8, respectively (P = .04). In multivariable analysis, a higher HLA disparity in the GVH direction using extended high-resolution typing (Risk ratio [RR] 2.8; 95% confidence interval [CI], 1.5 to 5.1; P = .0009) and first complete remission at time of transplantation (RR 2.1; 95% CI, 1.2 to 3.8; P = .01) were the only variables significantly associated with an improved disease-free survival. In conclusion, we found that in adults with AML undergoing single-unit UCBT, an increased number of HLA disparities at allele-level typing improved disease-free survival by decreasing the relapse rate without a negative effect on NRM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24516896

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  9 in total

Review 1.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

2.  Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Authors:  Claudio G Brunstein; Effie W Petersdorf; Todd E DeFor; Harriet Noreen; David Maurer; Margaret L MacMillan; Celalettin Ustun; Michael R Verneris; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-30       Impact factor: 5.742

3.  Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia.

Authors:  Jaime Sanz; Mi Kwon; Guiomar Bautista; Miguel A Sanz; Pascual Balsalobre; José Luis Piñana; Carlos Solano; Rafael Duarte; Christelle Ferrá; Ignacio Lorenzo; Carmen Martín; Pere Barba; María Jesús Pascual; Rodrigo Martino; Jorge Gayoso; Ismael Buño; Carmen Regidor; Almudena de la Iglesia; Juan Montoro; José Luis Díez-Martín; Guillermo F Sanz; Rafael Cabrera
Journal:  Blood Adv       Date:  2017-06-20

4.  Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.

Authors:  Masamichi Isobe; Takaaki Konuma; Masayoshi Masuko; Naoyuki Uchida; Shigesaburo Miyakoshi; Yasuhiro Sugio; Shuro Yoshida; Masatsugu Tanaka; Yoshiko Matsuhashi; Norimichi Hattori; Makoto Onizuka; Nobuyuki Aotsuka; Yasushi Kouzai; Atsushi Wake; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Ann Hematol       Date:  2021-02-23       Impact factor: 3.673

5.  Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.

Authors:  Eiman Hussein; Todd DeFor; John E Wagner; Darin Sumstad; Claudio G Brunstein; David H McKenna
Journal:  Transfusion       Date:  2019-11-22       Impact factor: 3.157

6.  Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

Authors:  Scott R Solomon; Michael T Aubrey; Xu Zhang; Katelin C Jackson; Lawrence E Morris; H Kent Holland; Melhem M Solh; Asad Bashey
Journal:  Blood Adv       Date:  2020-10-27

Review 7.  Strategies for Success With Umbilical Cord Haematopoietic Stem Cell Transplantation in Children With Malignant and Non-Malignant Disease Indications.

Authors:  Rob Wynn; Ramya Nataraj; Rubiya Nadaf; Kay Poulton; Alison Logan
Journal:  Front Cell Dev Biol       Date:  2022-04-06

Review 8.  Alternative Donor Transplantation for Acute Myeloid Leukemia.

Authors:  Nelli Bejanyan; Housam Haddad; Claudio Brunstein
Journal:  J Clin Med       Date:  2015-06-09       Impact factor: 4.241

Review 9.  Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia.

Authors:  Jodi J Lipof; Kah Poh Loh; Kristen O'Dwyer; Jane L Liesveld
Journal:  Cancers (Basel)       Date:  2018-06-04       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.